Table 2 Disease-related data of patients with myasthenia gravis.
From: A cross-sectional study on fear of progression in patients with myasthenia gravis
Variables | n | Percentage(%) |
|---|---|---|
MGFA | ||
Class I | 59 | 71.1 |
Class II | 19 | 22.9 |
Class III | 2 | 2.4 |
Class IV | 1 | 1.2 |
Class V | 2 | 2.4 |
MGFA I subtypes | ||
Pure ocular MG | 55 | 66.3 |
Residual ocular symptoms after generalization | 4 | 4.8 |
MG subtypes | ||
OMG | 59 | 71.1 |
EOMG | 13 | 15.7 |
LOMG | 9 | 10.8 |
TAMG | 2 | 2.4 |
Course of disease(year) | ||
<1 | 25 | 30.1 |
≥ 1<5 | 33 | 39.8 |
≥ 5<10 | 9 | 10.8 |
≥ 10 | 16 | 19.3 |
Progress of MG | ||
Yes | 31 | 37.3 |
No | 52 | 62.7 |
Crisis of MG | ||
Yes | 3 | 3.6 |
No | 80 | 96.4 |
Chronic comorbidities | ||
Yes | 40 | 48.2 |
No | 43 | 51.8 |
Thymoma | ||
Yes | 8 | 9.6 |
No | 75 | 90.4 |
Corticosteroids | ||
Yes | 51 | 61.4 |
No | 32 | 38.6 |
Immunosuppressant | ||
Yes | 51 | 61.4 |
No | 32 | 38.6 |
